Posted in News on April 6th, 2008 No Comments »
Raven biotech in stem cell collaboration Silicon Valley / San Jose …Bizjournals.com, NC - Apr 4, 2008Raven Biotechnologies Inc. said Friday it entered a collaboration with Bioprocessing Technology Institute to advance the discovery of novel cancer stem cell …Raven biotechnologies and Bioprocessing Technology Institute … PR Newswire (press release)all 14 news articles
Posted in News on April 6th, 2008 No Comments »
BioTime and International Stem Cell sign letter of intentTrading Markets (press release), CA - Apr 4, 2008… subsidiary Lifeline Cell Technology to jointly produce and distribute a wide array of research products from human embryonic stem cell technology. …
Posted in News on April 6th, 2008 No Comments »
KSL Adds Michigan Stem Cell GroupAdweek, NY - Apr 4, 2008NEW YORK Independent KSL Media has won the account of a Michigan public interest coalition that plans to promote the potential benefits of stem cell …
Posted in News on April 6th, 2008 No Comments »
Connecticut doles out nearly $10M in latest stem cell grantsBizjournals.com, NC - Apr 3, 2008The state of Connecticut says it has awarded $9.8 million in stem-cell research grants to scientists at Yale University and the University of Connecticut as …
Posted in Research on April 6th, 2008 No Comments »
“We are fortunate to work with Dr. Michael West, CEO of BioTime and Embryome Sciences. Dr. West is a leader in the emerging field of “embryomics”
Apr 3, 2008 - International Stem Cell Corporation and its wholly-owned subsidiary Lifeline Cell Technology have signed a letter of intent with BioTime, Inc., and BioTime’s wholly-owned subsidiary Embryome [...]
Posted in Research on April 6th, 2008 No Comments »
“Research in the United States has shown that transplanting a mixture of differentiated cells and stem cells can cause cancer, so the ability to isolate the pancreatic cells in the lab is a major boost in our bid to develop a successful therapy”
Washington, April 4: Scientists at the University of Manchester have made a [...]
Posted in Research on April 6th, 2008 No Comments »
“Cancer stem cells represent a promising new source of oncology drug targets”
Under the terms of the agreement, Raven will license its proprietary whole cell immunization technology for use with BTI’s stem cells. via Rehab Management
